A fusion intermediate state of HIV-1 gp41, targeted by broadly neutralizing antibodies, for purposes of vaccination

The Portal is a joint project of MATTO and the MTTC. The development and implementation of the portal has been paid for by the MTTC, Beth Israel Deaconess Medical Center, Boston Biomedical Research Institute, Boston University, Brandeis University, Caritas St. Elizabeth's Medical Center, Boston Children's Hospital, Dana Farber Cancer Institute, Harvard University, Joslin Diabetes Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, McLean Hospital, Northeastern University, The Schepens Eye Research Institute, and Tufts University.

Intellectual Property

ID:		3133
IP Type:		Licensable Technology
Title:		A fusion intermediate state of HIV-1 gp41, targeted by broadly neutralizing antibodies, for purposes of vaccination
Inventor:		Harrison, Stephen C.
Summary:		MARKETS ADDRESSED: During the past 15 years, several dozen HIV candidate vaccines have entered Phase I clinical trials. The candidate vaccines developed and tested to date have been safe and well tolerated, and nearly all, with varying degrees of success, have produced HIV-specific immune responses; several candidates have undergone, or are undergoing, Phase II evaluation. As of July 2005, two Phase III vaccine trials of first-generation rgp120 vaccine candidates have been completed; these trials failed to show efficacy. Functionally important epitopes of HIV glycoproteins are masked by glycosylation, trimerisation and receptor-induced conformational changes making it difficult to block with neutralizing antibodies. By focusing on transition state intermediates, such as gp41's pre-hairpin intermediate, broadly neutralizing antibodies may be produced, preventing issues from previous HIV vaccines from developing. INNOVATIONS & ADVANTAGES: HIV infection generally induces a strong antibody response to the envelope glycoprotein, the sole antigen on the virion surface. Most of the induced antibodies are ineffective in preventing infection, however, as they are either non-neutralizing or narrowly isolate-specific. Only three broadly neutralizing antibodies have been detected that recognize one of tree relatively conserved regions on the envelope protein: the CD4 binding site, carbohydrates on the outer gp120 surface, and a segment of the gp41 ectodomain. Conformational changes in gp120 result in its dissociation with gp41, leading to a cascade or refolding events in gp41. One of the transitional states of gp41 refolding is known as the "pre-hairpin intermediate." Use of a polypeptide similar to the prehairpin intermediate has been shown to induce broadly neutralizing antibodies against HIV.
Tech Type:		Vaccines
URL:		http://otd.harvard.edu/technologies/tech.php?case=3133
Contact:		Geff Erickson, (617) 432-0920
Organization:		Harvard University

Display all intellectual properties for Harrison, Stephen C.
Display all intellectual properties for Harvard University